The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin.
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin.
复制标题
lncRNA H19 通过稳定肌营养不良蛋白来缓解肌营养不良症。
DOI:
10.1038/s41556-020-00595-5
复制
发表时间:
2020-11
影响因子:
21.3
通讯作者:
Yang L
中科院分区:
文献类型:
--
作者:
Zhang Y;Li Y;Hu Q;Xi Y;Xing Z;Zhang Z;Huang L;Wu J;Liang K;Nguyen TK;Egranov SD;Sun C;Zhao Z;Hawke DH;Li J;Sun D;Kim JJ;Zhang P;Cheng J;Farida A;Hung MC;Han L;Darabi R;Lin C;Yang L
Dystrophin proteomic regulation in Muscular Dystrophies (MD) remains unclear. We report that a long noncoding RNA (lncRNA), H19, associates with dystrophin and inhibits E3 ligase-dependent poly-ubiquitination at Lys3584 (referred to as Ub-DMD) and its subsequent protein degradation. In-frame deletions in BMD and a DMD non-silent mutation (C3340Y) result in defects in the protein’s ability to interact with H19, causing elevated Ub-DMD levels and dystrophin degradation. Dmd C3333Y mice exhibited progressive muscular dystrophy, elevated serum CK, heart dilation, blood vessel irregularity, and respiratory failure with concurrently reduced dystrophin and increased Ub-DMD status. H19 RNA oligonucleotides conjugated with Agrin (AGR-H19) and Nifenazone competed-with/inhibited TRIM63. Dmd C3333Y animals, iPSC-derived skeletal muscle cells from BMD patients, or mdx mice subjected to exon-skipping exhibited inhibited dystrophin degradation, preserved skeletal/cardiac muscle histology, and improved strength/heart function following AGR-H19 or Nifenazone treatment. Our study paves the way to meaningful targeted therapeutics for BMD and certain DMD patients.
登录
查看更多内容
影响因子:
5.3
作者:
Barik, Arnab;Lu, Yisheng;Mei, Lin
通讯作者:
Mei, Lin
影响因子:
9.9
作者:
BROOKE, MH;FENICHEL, GM;ARFKEN, C
通讯作者:
ARFKEN, C
影响因子:
1.2
作者:
Conner, Jennifer D.;Wolden-Hanson, Tami;Quinn, LeBris S.
通讯作者:
Quinn, LeBris S.
影响因子:
5.3
作者:
Dormoy-Raclet, Virginie;Menard, Isabelle;Gallouzi, Imed-Eddine
通讯作者:
Gallouzi, Imed-Eddine
影响因子:
3.7
作者:
Chakraborty S;Christoforou N;Fattahi A;Herzog RW;Leong KW
通讯作者:
Leong KW